Skip to content
Trintellix, Brintellix(vortioxetine)
Brintellix, Trintellix (vortioxetine) is a small molecule pharmaceutical. Vortioxetine was first approved as Trintellix on 2013-09-30. It is used to treat major depressive disorder in the USA. It has been approved in Europe to treat major depressive disorder. The pharmaceutical is active against 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 1B, and sodium-dependent serotonin transporter. In addition, it is known to target 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 3A, and 5-hydroxytryptamine receptor 1D.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
Trintellix (generic drugs available since 2021-09-17)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vortioxetine hydrobromide
Tradename
Company
Number
Date
Products
TRINTELLIXTakedaN-204447 RX2013-09-30
3 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
trintellixNew Drug Application2023-01-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
major depressive disorderEFO_0003761D003865F22
Agency Specific
FDA
EMA
Expiration
Code
VORTIOXETINE HYDROBROMIDE, TRINTELLIX, TAKEDA PHARMS USA
2024-01-22M-187
2023-11-13M-267
Patent Expiration
Patent
Expires
Flag
FDA Information
Vortioxetine Hydrobromide, Trintellix, Takeda Pharms Usa
92780962032-03-21U-2436
87226842031-06-30DS, DP
89693552027-06-15U-1668
91259082027-06-15U-2309
91259092027-06-15U-2309
91259102027-06-15U-2309
92279462027-06-15U-1668
98616302027-06-15U-1668
114581342027-06-15DPU-3463
71448842026-06-17DS, DPU-1439
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06A: Antidepressants
— N06AX: Other antidepressants in atc
— N06AX26: Vortioxetine
HCPCS
No data
Clinical
Clinical Trials
100 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Major depressive disorderD003865EFO_0003761F22483113357
DepressionD003863F33.91125—8
Anxiety disordersD001008EFO_0006788F41.1—261—8
Healthy volunteers/patients—4——1—5
Cognitive dysfunctionD060825G31.84—1—2—3
Type 2 diabetes mellitusD003924EFO_0001360E11———2—2
Depressive disorderD003866EFO_1002014F32.A—1—1—2
DementiaD003704F03———1—1
Post-traumatic stress disordersD013313EFO_0001358F43.1———1—1
Hot flashesD019584———1—1
Show 8 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Treatment outcomeD016896——1——1
Radiation injuriesD011832T66——1——1
Hoarding disorderD000067836F42.3——1——1
Drug therapyD004358—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Binge-eating disorderD056912F50.2—1———1
AlcoholismD000437EFO_0003829F10.1—1———1
Attention deficit disorder with hyperactivityD001289EFO_0003888F90—1———1
Covid-19D000086382U07.1—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324I25.11————1
PharmacokineticsD0105991————1
Hepatic insufficiencyD0485501————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVORTIOXETINE
INNvortioxetine
Description
Vortioxetine is an N-arylpiperazine in which the aryl group is specified as 2-[(2,4-dimethylphenyl)sulfanyl]phenyl. Used (as its hydrobromide salt) for treatment of major depressive disorder. It has a role as an antidepressant, an anxiolytic drug, a serotonergic agonist and a serotonergic antagonist. It is a N-arylpiperazine and an aryl sulfide. It is a conjugate base of a vortioxetine(1+).
Classification
Small molecule
Drug classantidepressants (fluoxetine type): thioether derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1
Identifiers
PDB—
CAS-ID508233-74-7
RxCUI1455099
ChEMBL IDCHEMBL2104993
ChEBI ID76016
PubChem CID9966051
DrugBankDB09068
UNII ID3O2K1S3WQV (ChemIDplus, GSRS)
Target
Agency Approved
HTR1A
HTR1A
HTR7
HTR7
HTR1B
HTR1B
SLC6A4
SLC6A4
Organism
Homo sapiens
Gene name
HTR1A
Gene synonyms
ADRB2RL1, ADRBRL1
NCBI Gene ID
3350
Protein name
5-hydroxytryptamine receptor 1A
Protein synonyms
5-HT1a receptor, 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled, G-21, guanine nucleotide-binding regulatory protein-coupled receptor, Serotonin receptor 1A
Uniprot ID
Q6LAE7
Mouse ortholog
Htr1a (15550)
5-hydroxytryptamine receptor 1A (Q8BGS4)
Alternate
HTR2A
HTR2A
HTR6
HTR6
HTR5A
HTR5A
HTR2C
HTR2C
HTR3A
HTR3A
HTR1D
HTR1D
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
3356
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Q5T8C0
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Variants
Clinical Variant
No data
Financial
Trintellix - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,847 documents
View more details
Safety
Black-box Warning
Black-box warning for: Trintellix
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
245 adverse events reported
View more details